Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Autolus Therapeutics PLC Sponsored ADR AUTL

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
9.63%

Capital & Financial Ratios

Market Cap
511.03
Revenue
117.39
Net Income
(280.16)
Free Cash Flow
(232.73)
Net Debt
(125.40)
Current Ratio
4.89
Debt/Equity
1.04
P/E ratio
0.00
P/S ratio
4.40
P/B ratio
6.90
Past 5Y EPS Growth
21.36%
This Y EPS Growth
27.48%
Next Y EPS Growth
20.09%
Next 5Y EPS Growth
26.30%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
22.22%
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 240.34 589.45 302.21 203.13
Receivables — 0.02 24.02 44.39
Inventory — 4.14 33.21 33.43
Other — — — —
275.30 660.93 435.92 336.09
2023 2024 2025 Q'26
Payables 0.10 1.97 3.08 1.37
ST’ Debt — — — —
Other — 3.50 10.00 12.90
44.74 60.74 73.44 68.79
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 26.22 45.69 — —
—
’25 8.98 20.92 21.19 24.29
75.39
’24 10.09 — — 0.03
10.12
’23 1.29 — 0.41 0.00
1.70
’22 0.17 — 2.37 3.83
6.36
’21 0.27 1.65 0.24 0.18
2.33
’20 0.34 0.29 0.68 0.40
1.72
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (65.32) (25.07) — —
—
’25 (75.56) (72.78) (67.90) (67.32)
(283.57)
’24 (40.51) (51.08) (76.74) (37.93)
(206.27)
’23 (42.42) (38.15) (40.19) (24.83)
(145.59)
’22 (35.03) (30.81) (31.90) (14.57)
(112.31)
’21 (37.34) (36.61) (34.75) (9.16)
(117.86)
’20 (24.03) (26.93) (39.06) (27.73)
(117.76)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (68.00) (25.98) — —
—
’25 (83.81) (80.06) (80.40) (66.44)
(310.70)
’24 (41.05) (51.92) (86.33) (61.79)
(241.09)
’23 (46.04) (42.54) (41.69) (26.31)
(156.57)
’22 (35.80) (33.45) (38.70) (15.20)
(123.15)
’21 (39.24) (38.12) (38.61) (10.74)
(126.72)
’20 (26.67) (29.46) (43.11) (33.20)
(132.44)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.27) (0.15) — —
—
’25 (0.26) (0.18) (0.30) (0.34)
(1.08)
’24 (0.24) (0.22) (0.31) (0.09)
(0.86)
’23 (0.23) (0.26) (0.26) (0.44)
(1.20)
’22 (0.41) (0.46) (0.47) (0.23)
(1.57)
’21 (0.53) (0.47) (0.47) (0.51)
(1.97)
’20 (0.60) (0.62) (0.72) (0.82)
(2.76)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 1.60 1.61 2.07 1.11 — — —
Low Price
— — ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 5.59 6.94 7.45 2.80 — — —
High Price
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 399 463 647 752 — — —
Employees
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.02 0.00 0.02 0.10 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.36 1.70 10.12 75.39 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% (12.52%) (27.83%) — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (148.57) (208.40) (219.13) (285.56) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2,335.96%) (12,273.38%) (2,165.36%) (378.78%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (148.84) (208.38) (220.66) (287.53) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.42 6.57 7.72 9.81 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.07 0.01 0.04 0.28 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.57) (1.20) (0.86) (1.08) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.18) (0.84) (0.81) (1.07) ‡‡‡‡‡ — —
Cash Flow/Sh
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.11) (0.06) (0.14) (0.10) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.30) (0.90) (0.94) (1.17) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.14 0.64 1.67 0.67 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 94.99 173.94 255.16 266.14 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 27.16 215.42 56.97 7.03 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.59 10.67 1.40 2.97 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (27.66) 181.57 6.20 3.98 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.46 (6.37) (0.27) (0.93) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (112.31) (145.59) (206.27) (283.57) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (10.84) (10.99) (34.82) (27.13) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (123.15) (156.57) (241.09) (310.70) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 379.41 230.57 600.19 362.48 — — —
Working Cap'
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24.26 47.91 49.63 — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (358.50) (192.42) (539.82) (302.21) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 298.67 111.47 427.33 178.13 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (33.23%) (48.14%) (38.11%) (41.92%) ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (48.64%) (101.61%) (81.91%) (94.98%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Autolus Therapeutics (NASDAQ: AUTL), a leader in autologous CAR-T therapies for blood cancers and solid tumors, has suffered a brutal 97% stock decline from its 2018 peak, mirroring biotech busts like early Juno Therapeutics amid clinical delays, COVID disruptions, and relentless cash burn. Despite ballooning shares outstanding (6x since 2016) and widening losses—net income at -$221M in 2024 with ROE averaging -80%—the company has built a $540M net cash position and scaled manufacturing, yielding near-100% gross margins pre-2024 and revenue per employee rebounding to $15.6K. Book value per share holds at a reasonable $3.14 relative to lows near $1.60, but negative free cash flow (-$0.94/share) and capex ramps signal ongoing balance sheet strain.

Looking ahead, analysts forecast a sharp revenue inflection—from $10M in 2024 to $217M by 2027 (20x revenue/share growth)—fueled by catalysts like obe-cel’s BLA submission, FDA fast-tracks for AU-105, and positive trial data, potentially echoing Gilead’s Yescarta blockbuster path. Yet profitability lags, with EPS improving only modestly to -0.62 by 2027 amid projected -$212M losses, eroding BVPS 69%, and capex pressures keeping FCF negative. No insider buying adds caution, underscoring binary risks in a sector prone to trial flops and dilution.

At distressed multiples (PS 57x trailing, PB 1.4x), AUTL offers speculative value with analyst targets implying 260-830% upside if milestones hit, but macro headwinds and historical parallels (e.g., Clovis Oncology’s bankruptcy) demand vigilance. With 2+ years of cash runway, it suits patient, small-position investors—monitor 2025-2026 data closely for signs of margin recovery or further erosion.

Read full commentary →

Autolus Therapeutics PLC Sponsored ADR (AUTL) Latest News

News by impact score

Fine-tune

12 Sep

3 , 6:21 AM
AUCATZYL sales surge rapidly at Autolus while the company remains unprofitable. Rapid AUCATZYL sales growth indicates stronger product traction yet ongoing losses constrain profitability gains.

9 Sep

4 , 7:00 AM
Autolus Therapeutics receives FDA RMAT designation for obe-cel to treat systemic lupus erythematosus and lupus nephritis. RMAT designation grants regulatory advantages that accelerate obe-cel development and commercialization in new autoimmune indications.

11 Aug

3 www.marketbeat.com, 10:04 AM
Autolus Therapeutics reported Q2 financial results and pipeline updates during its earnings call, including revenue figures, operating expenses, cash position, and progress on clinical programs for its CAR-T therapies. Quarterly earnings and pipeline updates typically produce moderate short-term share price movement without altering long-term company trajectory.

3 , 7:00 AM
Autolus Therapeutics reported second quarter 2026 financial results and business updates. Quarterly financial results and business updates supply performance data that can shift near-term investor views on operations and valuation.

3 Aug

4 , 7:13 AM
Autolus Therapeutics reported preliminary second quarter 2026 net product revenue and announced a credit facility of up to $250 million with Perceptive Advisors. A $250 million credit facility marks a major strategic financing move that could significantly bolster Autolus Therapeutics' operational runway and development plans.

24 Jun

3 Simply Wall St., 7:11 AM
Autolus Therapeutics (AUTL) sees split analyst revisions after early Aucatyzl launch signals. Split analyst revisions on early Aucatyzl launch signals point to moderate effects on AUTL trajectory.

17 Jun

4 , 11:16 AM
Autolus Therapeutics (AUTL) appears less speculative as AUCATZYL revenue builds. AUCATZYL revenue growth directly improves Autolus Therapeutics financial trajectory and reduces stock risk profile.

21 May

3 GlobeNewswire, 5:10 PM
Autolus Therapeutics will present a clinical data update at the American Society of Clinical Oncology Annual Meeting 2026. Clinical data presentation at ASCO 2026 may moderately influence investor sentiment and company trajectory.

14 May

4 GuruFocus.com, 7:02 PM
Autolus Therapeutics PLC (AUTL) Q1 2026 earnings call highlights revenue surge and strategic advancements boosting outlook. Revenue surge and strategic moves in Q1 2026 earnings represent major positive shifts for AUTL's trajectory and investor sentiment.

4 www.marketbeat.com, 10:07 AM
Autolus Therapeutics released Q1 earnings call highlights covering financial results, pipeline progress, and strategic updates. Q1 earnings highlights detail financials and clinical advancements that could significantly sway investor sentiment and stock performance.

3 GlobeNewswire, 7:00 AM
Autolus Therapeutics reported first quarter 2026 financial results and business updates. Quarterly financial results and business updates affect financial performance and clinical progress, influencing investor sentiment moderately.

10 May

4 Insider Monkey, 12:01 AM
Autolus Therapeutics (AUTL) plans to cut 13% of its workforce while doubling manufacturing capacity by 2026. 13% workforce reduction cuts costs as capacity doubling supports scaled production and commercialization.

4 May

3 Simply Wall St., 4:16 PM
Analyst price target resets for Autolus Therapeutics (AUTL) are shifting the narrative around the company's prospects and stock performance. Analyst target resets influence market sentiment and investor perceptions of Autolus Therapeutics' trajectory.

29 Apr

3 GlobeNewswire, 4:05 PM
Autolus Therapeutics announces initiative to enhance operational efficiency and reduce costs. Cost reduction and efficiency measures can moderately improve financial runway and market sentiment without fundamentally altering core operations.

19 Apr

3 , 9:08 PM
Autolus Therapeutics (AUTL) investment narrative shifts as analysts recalibrate price targets and fair value estimates. Analyst recalibrations of targets and fair value moderately impact investor sentiment and market performance.

13 Apr

4 www.marketbeat.com, 11:43 AM
Autolus Therapeutics emphasizes AUCATZYL's safety for CAR-T advantage, expands treatment centers, and anticipates gross margin turnaround. AUCATZYL safety edge, center expansions, and margin turnaround boost Autolus's CAR-T competitiveness and financial outlook.

8 Apr

4 www.marketbeat.com, 3:12 PM
Autolus Therapeutics highlights obe-cel's momentum in ALL treatment with new real-world ROKA data and pediatric results. Positive real-world ROKA and pediatric data on obe-cel bolster Autolus's pipeline momentum in ALL, likely boosting investor sentiment and stock performance.

27 Mar

4 www.marketbeat.com, 10:07 AM
Autolus Therapeutics released highlights from its Q4 earnings call, covering financial results, operational updates, and future outlook for the biotech firm. Q4 earnings call highlights detail financial performance and strategic updates that could significantly shape investor sentiment and company trajectory.

4 GlobeNewswire, 7:00 AM
Autolus Therapeutics reported fourth quarter and full year 2025 financial results alongside business updates. Financial results and business updates signal major strategic progress in pipeline and operations, significantly impacting investor sentiment and trajectory.

5 Mar

4 www.marketbeat.com, 2:32 AM
Autolus Therapeutics projects $75 million in first-year revenue from Obe-cel launch and $120-135 million in 2026. Obe-cel launch with strong revenue forecasts represents a significant product milestone boosting future growth and investor sentiment.

4 Feb

3 , 8:57 AM
Autolus Therapeutics PLC has announced inducement grants under Nasdaq Listing Rule 5635(c)(4). These grants are aimed at attracting and retaining key personnel, which is essential for the company's growth and operational success. The move reflects the company's commitment to enhancing its workforce as it navigates the competitive landscape of the biotechnology sector. Inducement grants can positively influence talent acquisition and retention, impacting operational effectiveness and innovation.

30 Jan

4 Zacks, 6:08 AM
Autolus Therapeutics PLC Sponsored ADR (AUTL) has been identified as a strong sell due to ongoing challenges and negative market sentiment surrounding its operations and financial outlook. Analysts have raised concerns about the company's ability to achieve profitability and sustain growth, leading to a downgrade in its stock rating. Investors are advised to reconsider their positions as the company faces significant hurdles in the competitive landscape of biopharmaceuticals. Significant challenges in achieving profitability and growth are likely to impact investor sentiment and the company's market performance.

21 Jan

3 Simply Wall St., 7:05 AM
Autolus Therapeutics PLC Sponsored ADR (AUTL) is highlighted as one of three promising penny stocks with market capitalizations exceeding $70 million. The company is noted for its innovative cell therapy approaches, particularly in treating various cancers. Investors are encouraged to consider AUTL's potential for growth in the biotech sector, especially given its focus on advanced therapies and ongoing clinical trials. The company's innovative therapies and ongoing clinical trials may moderately influence its market performance and investor sentiment.

14 Jan

4 Simply Wall St., 9:09 AM
Autolus Therapeutics PLC has received approvals for AUCATZYL, which may significantly impact its long-term growth strategy. The company has also provided revenue guidance that could redefine investor expectations. These developments suggest a potential shift in the company's market position and financial outlook, attracting attention from investors and analysts alike. The approvals and revenue guidance are likely to significantly influence Autolus's future performance and market perception.

13 Jan

4 Simply Wall St., 5:09 AM
Autolus Therapeutics PLC has provided updated revenue guidance following the approvals of AUCATZYL in the UK and EU. These regulatory approvals are expected to enhance the company's market position and financial outlook, potentially leading to increased revenue streams. Investors are closely monitoring these developments as they could significantly influence Autolus's future performance. The approvals of AUCATZYL are significant regulatory milestones that could substantially impact the company's trajectory and investor sentiment.

12 Jan

4 GlobeNewswire, 7:00 AM
Autolus Therapeutics PLC reported preliminary unaudited net product revenue for the fourth quarter and full year 2025, highlighting advancements in its pipeline and providing an outlook for 2026. The company is focused on its strategic initiatives and product development to enhance its market position. Significant advancements in the pipeline and revenue projections indicate a potential shift in the company's trajectory and investor sentiment.

6 Jan

4 GlobeNewswire, 9:00 AM
Autolus Therapeutics PLC is set to evaluate the automated manufacturing of its product AUCATZYL® (obe-cel) using the Cellares Cell Shuttle™ Platform. This initiative aims to enhance production efficiency and scalability for the company's cell therapy offerings. The evaluation of automated manufacturing could significantly improve production capabilities and operational efficiency, impacting future performance.

4 Business Wire, 9:00 AM
Autolus Therapeutics PLC is set to evaluate the automated manufacturing of AUCATZYL® (obe-cel) using the Cellares Cell Shuttle™ platform. This initiative aims to enhance the production process for the company's cell therapy product, potentially improving efficiency and scalability in manufacturing. The evaluation of automated manufacturing could significantly enhance production capabilities and operational efficiency for AUCATZYL®, impacting future performance.

30 Dec

4 TipRanks, 8:05 AM
Needham has increased its price target for Autolus Therapeutics PLC Sponsored ADR (AUTL) and has named it a top pick for 2026, indicating strong confidence in the company's future prospects and potential growth in the biopharmaceutical sector. The upgrade in price target and designation as a top pick suggest significant positive sentiment and potential for future performance.

27 Dec

4 Insider MonkeyInsider MonkeyInsider MonkeyInsider MonkeyInsider Monkey, 7:43 AM
Autolus Therapeutics PLC is being considered as a potential high-reward investment opportunity. The company is involved in developing innovative therapies for cancer treatment, which could lead to significant financial returns. Analysts are evaluating its market position and future prospects, suggesting that it may be a stock worth considering for investors looking to capitalize on rapid growth. The company's advancements in cancer therapies and potential market shifts could significantly influence its future performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us